Trade Maravai Life Sciences Inc. - MRVI CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.07 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Maravai LifeSciences Holdings Inc ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 9.58 |
Open* | 9.99 |
1-Year Change* | -60.23% |
Day's Range* | 9.26 - 9.99 |
52 wk Range | 9.20-26.55 |
Average Volume (10 days) | 2.65M |
Average Volume (3 months) | 50.54M |
Market Cap | 2.78B |
P/E Ratio | 12.91 |
Shares Outstanding | 251.02M |
Revenue | 543.92M |
EPS | 0.86 |
Dividend (Yield %) | N/A |
Beta | -100.00K |
Next Earnings Date | Oct 31, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Sep 22, 2023 | 9.58 | -0.38 | -3.82% | 9.96 | 10.04 | 9.25 |
Sep 21, 2023 | 10.00 | 0.03 | 0.30% | 9.97 | 10.12 | 9.84 |
Sep 20, 2023 | 9.93 | -0.08 | -0.80% | 10.01 | 10.17 | 9.92 |
Sep 19, 2023 | 10.12 | 0.04 | 0.40% | 10.08 | 10.22 | 9.97 |
Sep 18, 2023 | 10.10 | -0.17 | -1.66% | 10.27 | 10.36 | 10.06 |
Sep 15, 2023 | 10.43 | 0.26 | 2.56% | 10.17 | 10.73 | 10.09 |
Sep 14, 2023 | 10.29 | 0.30 | 3.00% | 9.99 | 10.34 | 9.99 |
Sep 13, 2023 | 10.03 | -0.25 | -2.43% | 10.28 | 10.42 | 10.01 |
Sep 12, 2023 | 10.27 | 0.07 | 0.69% | 10.20 | 10.44 | 10.00 |
Sep 11, 2023 | 10.40 | -0.21 | -1.98% | 10.61 | 10.84 | 10.15 |
Sep 8, 2023 | 10.78 | 0.16 | 1.51% | 10.62 | 11.22 | 10.55 |
Sep 7, 2023 | 11.07 | 0.53 | 5.03% | 10.54 | 11.14 | 10.34 |
Sep 6, 2023 | 10.81 | 0.78 | 7.78% | 10.03 | 11.12 | 9.98 |
Sep 5, 2023 | 10.06 | -0.07 | -0.69% | 10.13 | 10.34 | 9.94 |
Sep 1, 2023 | 10.27 | -0.08 | -0.77% | 10.35 | 10.52 | 10.20 |
Aug 31, 2023 | 10.32 | 0.12 | 1.18% | 10.20 | 10.57 | 10.08 |
Aug 30, 2023 | 10.29 | -0.05 | -0.48% | 10.34 | 10.45 | 10.12 |
Aug 29, 2023 | 10.39 | 0.04 | 0.39% | 10.35 | 10.58 | 10.31 |
Aug 28, 2023 | 10.28 | 0.30 | 3.01% | 9.98 | 10.56 | 9.92 |
Aug 25, 2023 | 10.38 | 0.28 | 2.77% | 10.10 | 10.46 | 9.94 |
Maravai Life Sciences Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Thursday, September 28, 2023 | ||
Time (UTC) 14:00 | Country US
| Event Maravai LifeSciences Holdings Inc To Host R&D Day Maravai LifeSciences Holdings Inc To Host R&D DayForecast -Previous - |
Tuesday, October 31, 2023 | ||
Time (UTC) 10:59 | Country US
| Event Q3 2023 Maravai LifeSciences Holdings Inc Earnings Release Q3 2023 Maravai LifeSciences Holdings Inc Earnings ReleaseForecast -Previous - |
Tuesday, November 14, 2023 | ||
Time (UTC) 10:59 | Country US
| Event Maravai LifeSciences Holdings Inc at Jefferies London Healthcare Conference Maravai LifeSciences Holdings Inc at Jefferies London Healthcare ConferenceForecast -Previous - |
Tuesday, February 20, 2024 | ||
Time (UTC) 21:00 | Country US
| Event Q4 2023 Maravai LifeSciences Holdings Inc Earnings Release Q4 2023 Maravai LifeSciences Holdings Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 883.001 | 799.24 | 284.098 | 143.14 | 123.833 |
Revenue | 883.001 | 799.24 | 284.098 | 143.14 | 123.833 |
Cost of Revenue, Total | 168.957 | 140.561 | 79.649 | 66.849 | 60.765 |
Gross Profit | 714.044 | 658.679 | 204.449 | 76.291 | 63.068 |
Total Operating Expense | 308.993 | 244.595 | 171.788 | 119.152 | 113.019 |
Selling/General/Admin. Expenses, Total | 129.259 | 100.064 | 94.245 | 40.354 | 33.194 |
Research & Development | 15.569 | 9.319 | 1.704 | 3.627 | 4.499 |
Depreciation / Amortization | 2.8 | 5.9 | 7.6 | 8 | 8 |
Unusual Expense (Income) | 0.208 | -11.249 | -11.41 | 0 | 5.622 |
Other Operating Expenses, Total | -7.8 | 0 | 0 | 0.322 | 0.939 |
Operating Income | 574.008 | 554.645 | 112.31 | 23.988 | 10.814 |
Interest Income (Expense), Net Non-Operating | -18.076 | -30.26 | -30.74 | -29.959 | -27.399 |
Other, Net | -4.46 | 6.38 | 0.126 | 0.118 | 0.087 |
Net Income Before Taxes | 551.472 | 530.765 | 81.696 | -5.853 | -16.498 |
Net Income After Taxes | 490.663 | 469.25 | 78.816 | -5.201 | -16.915 |
Minority Interest | -270.458 | -287.213 | 13.342 | 2.4 | 4.446 |
Net Income Before Extra. Items | 220.205 | 182.037 | 92.158 | -2.801 | -12.469 |
Net Income | 220.205 | 182.037 | 92.158 | -2.801 | -12.469 |
Total Adjustments to Net Income | -15.27 | -5.68 | -5.259 | ||
Income Available to Common Excl. Extra. Items | 220.205 | 182.037 | 76.888 | -8.481 | -17.728 |
Income Available to Common Incl. Extra. Items | 220.205 | 182.037 | 76.888 | -8.481 | -17.728 |
Diluted Net Income | 426.276 | 402.356 | 76.888 | -8.481 | -17.728 |
Diluted Weighted Average Shares | 255.323 | 257.803 | 257.621 | 257.621 | 257.621 |
Diluted EPS Excluding Extraordinary Items | 1.66956 | 1.56071 | 0.29845 | -0.03292 | -0.06881 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
Diluted Normalized EPS | 1.7403 | 1.52746 | 0.27165 | -0.03292 | -0.05463 |
Dilution Adjustment | 206.071 | 220.319 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 68.914 | 79.025 | 204.713 | 191.263 | 487.025 |
Revenue | 68.914 | 79.025 | 204.713 | 191.263 | 487.025 |
Cost of Revenue, Total | 43.273 | 33.676 | 53.253 | 38.176 | 77.528 |
Gross Profit | 25.641 | 45.349 | 151.46 | 153.087 | 409.497 |
Total Operating Expense | 80.528 | 76.492 | 95.467 | 74.36 | 139.166 |
Selling/General/Admin. Expenses, Total | 34.677 | 37.971 | 37.203 | 30.095 | 59.761 |
Research & Development | 4.194 | 4.145 | 4.411 | 5.389 | 7.969 |
Depreciation / Amortization | 0.7 | 0.7 | 0.6 | 0.7 | 1.5 |
Unusual Expense (Income) | 0 | 0 | 0 | 0 | 0.208 |
Operating Income | -11.614 | 2.533 | 109.246 | 116.903 | 347.859 |
Interest Income (Expense), Net Non-Operating | -0.231 | -5.788 | -7.842 | -3.136 | -7.098 |
Other, Net | -1.519 | -1.268 | -5.528 | -0.004 | 1.072 |
Net Income Before Taxes | -13.364 | -4.523 | 95.876 | 113.763 | 341.833 |
Net Income After Taxes | -11.943 | -1.348 | 87.429 | 99.653 | 303.581 |
Minority Interest | 5.402 | 1.281 | -49.795 | -55.184 | -165.479 |
Net Income Before Extra. Items | -6.541 | -0.067 | 37.634 | 44.469 | 138.102 |
Net Income | -6.541 | -0.067 | 37.634 | 44.469 | 138.102 |
Income Available to Common Excl. Extra. Items | -6.541 | -0.067 | 37.634 | 44.469 | 138.102 |
Income Available to Common Incl. Extra. Items | -6.541 | -0.067 | 37.634 | 44.469 | 138.102 |
Diluted Net Income | -6.541 | -0.067 | 75.161 | 44.487 | 306.628 |
Diluted Weighted Average Shares | 131.864 | 131.739 | 131.626 | 131.651 | 193.487 |
Diluted EPS Excluding Extraordinary Items | -0.0496 | -0.00051 | 0.57102 | 0.33792 | 1.58475 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.03069 | 0.02789 | 0.58965 | 0.35893 | 1.63859 |
Total Adjustments to Net Income | |||||
Dilution Adjustment | 37.527 | 0.018 | 168.526 | ||
Other Operating Expenses, Total | -2.316 | 0 | 0 | -7.8 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 847.902 | 740.039 | 331.598 | 60.552 | 53.802 |
Cash and Short Term Investments | 632.138 | 551.272 | 236.184 | 24.7 | 21.866 |
Cash | 632.138 | 551.272 | 236.184 | 24.7 | 21.866 |
Total Receivables, Net | 146.814 | 117.512 | 51.218 | 18.83 | 15.991 |
Accounts Receivable - Trade, Net | 138.624 | 117.512 | 51.218 | 18.83 | 15.991 |
Total Inventory | 43.152 | 51.557 | 33.301 | 14.202 | 14.308 |
Prepaid Expenses | 25.798 | 19.698 | 10.895 | 2.82 | 1.637 |
Total Assets | 2282.31 | 1918.28 | 1270.69 | 577.796 | 539.676 |
Property/Plant/Equipment, Total - Net | 116.59 | 95.427 | 101.305 | 94.311 | 42.578 |
Property/Plant/Equipment, Total - Gross | 136.092 | 107.959 | 111.952 | 102.41 | 31.492 |
Accumulated Depreciation, Total | -19.502 | -12.532 | -10.647 | -8.099 | -4.289 |
Goodwill, Net | 283.668 | 152.766 | 224.275 | 224.275 | 224.275 |
Intangibles, Net | 216.663 | 117.571 | 177.656 | 197.853 | 218.127 |
Other Long Term Assets, Total | 817.492 | 812.473 | 435.857 | 0.805 | 0.894 |
Total Current Liabilities | 110.144 | 93.777 | 130.778 | 29.562 | 35.919 |
Accounts Payable | 5.991 | 8.154 | 8.171 | 7.478 | 3.604 |
Accrued Expenses | 50.629 | 29.34 | 29.014 | 16.515 | 11.147 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 5.44 | 6 | 6 | 2.5 | 2.5 |
Other Current Liabilities, Total | 48.084 | 50.283 | 87.593 | 3.069 | 18.668 |
Total Liabilities | 1737.1 | 1602.78 | 1182.18 | 436.4 | 395.271 |
Total Long Term Debt | 521.997 | 524.591 | 584.781 | 387.702 | 337.389 |
Long Term Debt | 521.997 | 524.591 | 528.614 | 334.783 | 335.55 |
Capital Lease Obligations | 0 | 56.167 | 52.919 | 1.839 | |
Deferred Income Tax | 0 | 8.609 | 14.697 | 15.856 | |
Minority Interest | 360.025 | 229.862 | 66.235 | 3.231 | 3.611 |
Other Liabilities, Total | 744.931 | 754.547 | 391.777 | 1.208 | 2.496 |
Total Equity | 545.218 | 315.499 | 88.511 | 141.396 | 144.405 |
Common Stock | 2.554 | 2.552 | 2.576 | 183.91 | 182.809 |
Retained Earnings (Accumulated Deficit) | 404.766 | 184.561 | 0.854 | -42.381 | -38.237 |
Other Equity, Total | 0 | -0.044 | -0.133 | -0.167 | |
Total Liabilities & Shareholders’ Equity | 2282.31 | 1918.28 | 1270.69 | 577.796 | 539.676 |
Total Common Shares Outstanding | 255.361 | 255.157 | 257.621 | 257.621 | 257.621 |
Additional Paid-In Capital | 137.898 | 128.386 | 85.125 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 765.513 | 847.902 | 835.526 | 759.382 | 619.135 |
Cash and Short Term Investments | 628.273 | 632.138 | 617.446 | 550.676 | 431.469 |
Cash | 628.273 | 632.138 | 617.446 | 550.676 | 431.469 |
Total Receivables, Net | 56.889 | 146.814 | 132.224 | 128.929 | 120.355 |
Accounts Receivable - Trade, Net | 56.273 | 138.624 | 114.069 | 120.354 | 120.355 |
Total Inventory | 54.819 | 43.152 | 62.424 | 60.113 | 51.409 |
Prepaid Expenses | 25.532 | 25.798 | 23.432 | 19.664 | 15.902 |
Total Assets | 2315.39 | 2282.31 | 2248.9 | 2171.8 | 2043.23 |
Property/Plant/Equipment, Total - Net | 87.721 | 116.59 | 102.538 | 94.185 | 47.702 |
Goodwill, Net | 326.569 | 283.668 | 283.535 | 283.535 | 283.535 |
Intangibles, Net | 241.578 | 216.663 | 222.899 | 229.153 | 235.405 |
Other Long Term Assets, Total | 894.007 | 817.492 | 804.401 | 805.544 | 857.453 |
Total Current Liabilities | 124.896 | 110.144 | 115.655 | 112.53 | 86.675 |
Accounts Payable | 4.784 | 5.991 | 9.459 | 23.267 | 10.384 |
Accrued Expenses | 70.065 | 50.629 | 48.181 | 34.581 | 32.411 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 5.74 | 5.44 | 5.44 | 5.44 | 5.44 |
Other Current Liabilities, Total | 44.307 | 48.084 | 52.575 | 49.242 | 38.44 |
Total Liabilities | 1793.87 | 1737.1 | 1745.14 | 1715.21 | 1660.67 |
Total Long Term Debt | 537.73 | 521.997 | 522.824 | 523.655 | 524.499 |
Long Term Debt | 521.161 | 521.997 | 522.824 | 523.655 | 524.499 |
Capital Lease Obligations | 16.569 | ||||
Deferred Income Tax | 8.68 | ||||
Minority Interest | 379.121 | 360.025 | 337.908 | 317.204 | 271.743 |
Other Liabilities, Total | 743.444 | 744.931 | 768.751 | 761.822 | 777.754 |
Total Equity | 521.517 | 545.218 | 503.761 | 456.588 | 382.559 |
Common Stock | 2.509 | 2.554 | 2.552 | 2.552 | 2.552 |
Additional Paid-In Capital | 114.309 | 137.898 | 134.077 | 131.373 | 128.584 |
Retained Earnings (Accumulated Deficit) | 404.699 | 404.766 | 367.132 | 322.663 | 251.423 |
Other Equity, Total | |||||
Total Liabilities & Shareholders’ Equity | 2315.39 | 2282.31 | 2248.9 | 2171.8 | 2043.23 |
Total Common Shares Outstanding | 250.883 | 255.361 | 255.209 | 255.208 | 255.159 |
Other Current Assets, Total |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 490.663 | 469.25 | 78.816 | -5.201 | -16.915 |
Cash From Operating Activities | 535.977 | 368.57 | 152.187 | 24.115 | -0.186 |
Cash From Operating Activities | 7.566 | 6.413 | 5.517 | 3.81 | 2.225 |
Amortization | 24.269 | 18.339 | 20.32 | 20.274 | 20.122 |
Deferred Taxes | 42.318 | 46.904 | -5.464 | -1.159 | 0.317 |
Non-Cash Items | 16.243 | 4.295 | 17.105 | 4.101 | 9.906 |
Cash Taxes Paid | 23.032 | 22.473 | 5.006 | -0.802 | -0.097 |
Cash Interest Paid | 20.198 | 27.234 | 28.916 | 28.728 | 25.678 |
Changes in Working Capital | -45.082 | -176.631 | 35.893 | 2.29 | -15.841 |
Cash From Investing Activities | -267.612 | 105.655 | 6.068 | -17.148 | -3.451 |
Capital Expenditures | -17.09 | -14.85 | -25.408 | -17.148 | -3.611 |
Other Investing Cash Flow Items, Total | -250.522 | 120.505 | 31.476 | 0 | 0.16 |
Cash From Financing Activities | -187.499 | -159.049 | 53.212 | -4.167 | -9.167 |
Financing Cash Flow Items | -184.417 | -154.758 | -444.983 | -1.527 | -64.595 |
Issuance (Retirement) of Debt, Net | -5.44 | -6 | 196.924 | -2.64 | 55.428 |
Foreign Exchange Effects | 0 | -0.088 | 0.017 | 0.034 | -0.069 |
Net Change in Cash | 80.866 | 315.088 | 211.484 | 2.834 | -12.873 |
Issuance (Retirement) of Stock, Net | 2.358 | 1.709 | 301.271 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -1.348 | 490.663 | 403.234 | 303.581 | 146.86 |
Cash From Operating Activities | 85.074 | 535.977 | 436.642 | 326.583 | 162.304 |
Cash From Operating Activities | 2.08 | 7.566 | 5.604 | 3.747 | 1.855 |
Amortization | 6.765 | 24.269 | 18.033 | 11.779 | 5.527 |
Deferred Taxes | -1.52 | 42.318 | 35.307 | 26.073 | 13.217 |
Non-Cash Items | 10.756 | 16.243 | 3.785 | 0.769 | 3.083 |
Cash Taxes Paid | 0.521 | 23.032 | 19.581 | 13.856 | 0.914 |
Cash Interest Paid | 9.593 | 20.198 | 11.416 | 6.132 | 1.373 |
Changes in Working Capital | 68.341 | -45.082 | -29.321 | -19.366 | -8.238 |
Cash From Investing Activities | -69.73 | -267.612 | -249.092 | -243.245 | -241.584 |
Capital Expenditures | -7.868 | -17.09 | -10.876 | -4.409 | -2.748 |
Other Investing Cash Flow Items, Total | -61.862 | -250.522 | -238.216 | -238.836 | -238.836 |
Cash From Financing Activities | -19.209 | -187.499 | -121.376 | -83.934 | -40.523 |
Financing Cash Flow Items | -17.516 | -184.417 | -119.289 | -82.477 | -39.889 |
Issuance (Retirement) of Stock, Net | -0.333 | 2.358 | 1.993 | 1.263 | 0.726 |
Issuance (Retirement) of Debt, Net | -1.36 | -5.44 | -4.08 | -2.72 | -1.36 |
Foreign Exchange Effects | 0 | 0 | 0 | 0 | |
Net Change in Cash | -3.865 | 80.866 | 66.174 | -0.596 | -119.803 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Maravai Life Sciences Inc. Company profile
Maravai Life Sciences Inc. provides in vitro diagnostic products, diagnostic laboratory services, and life sciences tools. The company was founded in 2014 and is based in San Diego, California.Industry: | Bio Diagnostics & Testing |
10770 Wateridge Circle Suite 200
Suite 200
SAN DIEGO
CALIFORNIA 92121
US
Income Statement
- Annual
- Quarterly
News

EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com